ACBMOTCServices-Amusement & Recreation ServicesFiscal year ends December 31

ACRO BIOMEDICAL CO., LTD.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.03+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $1.56M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Acro Biomedical reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Acro Biomedical's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Acro Biomedical's annual and quarterly filings with the SEC
Per-share figures adjusted for the 3-for-1 split on May 18, 2017
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ACBM.

Company	Revenue	Growth
ACBM	$0	–
VEST	$0	–
ADTI	–	–
LVRLF	–	–
CPOP	–	–
SFRX	–	–

Company

Exchange: OTC
Industry: Services-Amusement & Recreation Services
Fiscal year ends: December 31
Employees: 1
Auditor: Weinberg & Company, P.A.
SEC CIK: 1622996

Advertisement
300 × 250